Cwm, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Cwm, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	BUY	$38.96 - $42.75 $818 - $897	21 Added 10.29%	225 $9,000
Q1 2024 Apr 05, 2024	BUY	$40.88 - $43.27 $81 - $86	2 Added 0.99%	204 $9,000
Q4 2023 Feb 01, 2024	SELL	$20.27 - $42.44 $3,060 - $6,408	-151 Reduced 42.78%	202 $9,000
Q3 2023 Oct 11, 2023	BUY	$20.26 - $31.91 $6,665 - $10,498	329 Added 1370.83%	353 $8,000
Q2 2023 Aug 03, 2023	SELL	$23.9 - $35.38 $262 - $389	-11 Reduced 31.43%	24 $1,000
Q1 2023 Apr 28, 2023	BUY	$22.82 - $35.32 $228 - $353	10 Added 40.0%	35 $1,000
Q2 2022 Jul 28, 2022	BUY	$20.62 - $37.15 $247 - $445	12 Added 92.31%	25 $1,000
Q1 2022 Apr 21, 2022	BUY	$23.5 - $35.38 $305 - $459	13 New	13 $0

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

Stay updated on Cwm, LLC with notifications on news.